Risk assessment of kINPen plasma treatment of four human pancreatic cancer cell lines with respect to metastasis

dc.bibliographicCitation.firstPage1237eng
dc.bibliographicCitation.issue9eng
dc.bibliographicCitation.volume11eng
dc.contributor.authorBekeschus, Sander
dc.contributor.authorFreund, Eric
dc.contributor.authorSpadola, Chiara
dc.contributor.authorPrivat-Maldonado, Angela
dc.contributor.authorHackbarth, Christine
dc.contributor.authorBogaerts, Annemie
dc.contributor.authorSchmidt, Anke
dc.contributor.authorWende, Kristian
dc.contributor.authorWeltmann, Klaus-Dieter
dc.contributor.authorWoedtke, Thomas von
dc.contributor.authorHeidecke, Claus-Dieter
dc.contributor.authorPartecke, Lars-Ivo
dc.contributor.authorKäding, André
dc.date.accessioned2021-10-18T08:40:57Z
dc.date.available2021-10-18T08:40:57Z
dc.date.issued2019
dc.description.abstractCold physical plasma has limited tumor growth in many preclinical models and is, therefore, suggested as a putative therapeutic option against cancer. Yet, studies investigating the cells’ metastatic behavior following plasma treatment are scarce, although being of prime importance to evaluate the safety of this technology. Therefore, we investigated four human pancreatic cancer cell lines for their metastatic behavior in vitro and in chicken embryos (in ovo). Pancreatic cancer was chosen as it is particularly metastatic to the peritoneum and systemically, which is most predictive for outcome. In vitro, treatment with the kINPen plasma jet reduced pancreatic cancer cell activity and viability, along with unchanged or decreased motility. Additionally, the expression of adhesion markers relevant for metastasis was down-regulated, except for increased CD49d. Analysis of 3D tumor spheroid outgrowth showed a lack of plasma-spurred metastatic behavior. Finally, analysis of tumor tissue grown on chicken embryos validated the absence of an increase of metabolically active cells physically or chemically detached with plasma treatment. We conclude that plasma treatment is a safe and promising therapeutic option and that it does not promote metastatic behavior in pancreatic cancer cells in vitro and in ovo. © 2019 by the authors.eng
dc.description.versionpublishedVersioneng
dc.identifier.urihttps://oa.tib.eu/renate/handle/123456789/7001
dc.identifier.urihttps://doi.org/10.34657/6048
dc.language.isoengeng
dc.publisherBasel : MDPI AGeng
dc.relation.doihttps://doi.org/10.3390/cancers11091237
dc.relation.essn2072-6694
dc.relation.ispartofseriesCancers 11 (2019), Nr. 9eng
dc.rights.licenseCC BY 4.0 Unportedeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/eng
dc.subjectCell adhesioneng
dc.subjectOncologyeng
dc.subjectPlasma medicineger
dc.subject.ddc610eng
dc.titleRisk assessment of kINPen plasma treatment of four human pancreatic cancer cell lines with respect to metastasiseng
dc.typearticleeng
dc.typeTexteng
dcterms.bibliographicCitation.journalTitleCancerseng
tib.accessRightsopenAccesseng
wgl.contributorINPeng
wgl.subjectMedizin, Gesundheiteng
wgl.typeZeitschriftenartikeleng
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
cancers-11-01237.pdf
Size:
4.98 MB
Format:
Adobe Portable Document Format
Description:
Collections